BEATS= 1
CYCLELENGTH=  857
IGNORE_STEADY_STATE ENDO MID EPI
MYOCYTE= NORMAL  $FEMALE $ MODIFIED or NORMAL + MALE OR FEMALE (AT 600bcl) or NORMAL PIG $ FDA model optimization
ON_DRUGS= NO
$------------------------
CONDUCTANCES
$!! Male Phenotype. Female Phenotype is commented below!!
INAME= HUMAN
$---1 conductance ito channel (GIto)
1.0 1.0 1.0 
$---2 conductance slow potassium channel (GKs) ****
1.0 1.0 1.0 
$---3 conductance potassium channel (GK1)  ****
1.0 1.0 1.0 
$---4 conductance rapid potassium channel (GKr) ****
1.0 1.0 1.0 
$---5 conductance sodium channel (GNa)  ****
1.0 1.0 1.0
$---6 conductance late sodium channel (GNaL)  ****
1.0 1.0 1.0 
$---7 conductance sodium calcium exchanger (GNaCa) ****
1.0 1.0 1.0
$---8 background potassium background current conductance (gKb) ****
1.0 1.0 1.0
$---9 L-type calcium current permeability (pCa equiv to gCaL)  ****
1.0 1.0 1.0 
$---10 sodium potassium pump current permeability (pNaK)
1.0 1.0 1.0 
$---11 Calmodulin
1.0 1.0 1.0 
$---12 Serca Pump (Jup)
1.0 1.0 1.0 
$---13 Sodium, Calcium, Potassium
1.0 1.0 1.0
END_CONDUCTANCES
$------------------------
 DOSIS
  INAME= AMIODARONE
$--- Dosis to affect L-type Calcium current (ICaL_dosis)
   0.0
$--- IC50 of L-type Calcium current (ICAL_IC50)
   270.0       
$--- Dosis to affect the Rapid Potassium Current (KR_DOSIS)
   0.0
$--- IC50 of Rapid Potasium Current (IKR_IC50)
   30.0  
$--- Dosis to affect the Sodium Channel (NA_DOSIS)
   0.0  
$--- IC50 of Sodium Channel (INA_IC50)
   4800.0 
$--- Dosis to affect the ITO Channel (ITO_DOSIS)
   0.0  
$--- IC50 of ITO Channel (ITO_IC50)
   4800.0 
 END_DOSIS
